statementSaid on 2026-11-11
Xinhua Pharmaceutical's OAB-14 dry suspension has completed enrollment of the first patient in China for Phase II clinical trials; Gaoguang Pharmaceutical's brain-penetrant TYK2/JAK1 inhibitor TLL-041 is positioned as a neurodegenerative disease candidate with global first-in-class potential.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
新華製藥OAB-14乾混懸劑已完成Ⅱ期臨床中國首例患者入組;仍處IPO階段的高光製藥,其腦滲透性TYK2/JAK1抑制劑TLL-041被定位為具有全球首創潛力的神經退行性疾病候選藥物。